<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191254</url>
  </required_header>
  <id_info>
    <org_study_id>1138.4</org_study_id>
    <nct_id>NCT02191254</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency</brief_title>
  <official_title>A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients
      with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location,
      Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in limb volume determination</measure>
    <time_frame>Baseline, day 84</time_frame>
    <description>water displacement method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in limb volume determination</measure>
    <time_frame>Baseline, day 21 and day 42</time_frame>
    <description>water displacement method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the calf circumference</measure>
    <time_frame>Baseline, at day 21, 42 and 84</time_frame>
    <description>in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the ankle circumference</measure>
    <time_frame>Baseline, at day 21, 42, and 84</time_frame>
    <description>in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)</measure>
    <time_frame>Baseline, at day 21, 42, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)</measure>
    <time_frame>day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by the investigator on a 4-point VRS</measure>
    <time_frame>day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by the patient on a 4-point VRS</measure>
    <time_frame>day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by the investigator on a 4-point VRS</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in laboratory values</measure>
    <time_frame>Baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))</measure>
    <time_frame>Baseline, up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Antistax®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antistax®</intervention_name>
    <arm_group_label>Antistax®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18 years of age or older

          -  CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease,
             e.g. pigmentation), according to the CEAP classification

          -  Willing and able to give written informed consent prior to participation in the study

        Exclusion Criteria:

        Concomitant diseases:

          -  Decompensated cardiac insufficiency

          -  Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency,
             renal insufficiency, lymphoedema, etc)

          -  Peripheral arterial disease (ankle/arm pressure index &lt; 0.9)

          -  Current acute phlebitis or thrombosis

          -  Renal insufficiency (serum creatinine &gt; 1.5 mg/dl)

          -  Liver disease (SGPT &gt; 3x upper limit of normal)

          -  Other diseases: hyper- or hypocalcaemia, malignancies

          -  Anamnestic indications of diabetic microangiopathy or polyneuropathy

          -  Drug and/or alcohol abuse

          -  Severe climacteric complaints: changes in, or initiation with post-menopausal hormone
             replacement therapy within the last 3 months

          -  Immobility

          -  Avalvulia

          -  Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus,
             Haemangiectasia hypertrophicans)

          -  State after pulmonary embolism

          -  Recognised hypersensitivity to the trial drug ingredients

          -  Current florid venous ulcus

          -  Clinical indication for a necessary, specific phlebologic acute treatment, e.g.
             compression treatment, phlebectomy, etc.

        Previous treatments:

          -  Patients who are on compression therapy and/or are wearing support stockings and who
             optimally benefit from these measures

          -  Treatment with venous drugs within the last 2 weeks prior to the intake of study
             medication

          -  Changes in or unstable response to treatment with theophylline, diuretics, cardiac
             glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks
             prior to the intake of study medication

        Concomitant treatment/non-drug therapy exclusion criteria:

          -  Other venous drugs apart from the trial medication

          -  Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry

          -  Extensive use of laxatives

          -  Major surgery requiring full anaesthesia

        Other exclusion criteria:

          -  Previously studied under this protocol

          -  Participation in another clinical trial within the previous 90 days or during the
             present study

          -  Patient is investigator, co-investigator, or study nurse in this study

          -  Pregnant or nursing women or inadequate birth control methods (this applies to females
             of childbearing potential only)

          -  Patients considered as mentally ill as well as unable to work or with limited working
             ability, or unable (or only partially able) to follow the spoken or written
             explanations concerning the trial

          -  Patients in a bad general health state according to the investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

